Harmony Biosciences Holdings, Inc.
NASDAQ:HRMYBiotechnology
-$0.61 today
- Market cap
- $1.94B
- Beta
- 0.97
- P/E (TTM)
- 13.2
- EPS (TTM)
- $2.52
Volume 0.57M
Average 0.82M
HRMY Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Harmony Biosciences Holdings, Inc.NASDAQ: HRMY
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns negative
Q2 FY2026 accounts payables was -$6.92M, compared with $10.84M a year earlier. Trailing-twelve-month accounts payables was -$4.66M.
Context
- Accounts payables amounted to 0.5% of revenue in FY2025, down 0.3 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near -$6.92M or moves back toward the trailing-twelve-month quarterly average of -$1.16M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 3.95M USD
- Year-over-year change
- +173.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.95M | +173.3% |
| FY2024 | 2024-12-31 | (5.38M) | -160.2% |
| FY2023 | 2023-12-31 | 8.95M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Payables vs competitors
How HRMY compares with its peers on the latest reported figures
- HRMY's LTM Jun 2026 accounts payables of $4.66M is the 2nd largest of the 4 companies compared; the peer median is $1.81M.
- Its year-over-year change of -133.1% is the lowest of 2, against a peer median of +305.3%.
- Accounts payables amounts to 0.5% of revenue for HRMY.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $5.43M | — | — | — |
| LTM Jun 2026 | $4.66M | -133.1% | — | 0.5% | |
| LTM Mar 2026 | $1.81M | +305.3% | -6.6% | — | |
| LTM Jun 2026 | $423.37K | — | +6.2% | — | |
APMDApnimed, Inc. | — | — | — | — | — |
| Peer median (excluding HRMY) | $1.81M | +305.3% | -0.2% | — | |
Competitors are the stored peer set for HRMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 34.6M | 181.47M | 128.85M | 145.49M | 158.69M |
| Depreciation & Amortization | 18.84M | 23.39M | 24.36M | 24.11M | 25.34M |
| Deferred Income Tax | 0 | 0 | (13.42M) | (29.3M) | 0 |
| Stock-Based Compensation | 16.11M | 26.91M | 31.71M | 42.6M | 44.9M |
| Change in Working Capital | 2.19M | (6.89M) | 35.04M | (7.32M) | 91.82M |
| Accounts Receivables | (12.67M) | (19.9M) | (19.4M) | (8.89M) | (13.75M) |
| Inventory | (609K) | 135K | (1.07M) | (1.84M) | 1.84M |
| Accounts Payables | 0 | 0 | 8.95M | (5.38M) | 3.95M |
| Other Working Capital | 15.46M | 12.87M | 46.55M | 8.79M | 99.78M |
| Other Non-Cash Items | 26.83M | (80.4M) | 12.85M | 44.23M | 27.47M |
| Operating Cash Flow | 98.56M | 144.47M | 219.39M | 219.82M | 348.2M |
| Capital Expenditures | (298K) | (172K) | (312K) | (1.15M) | (310K) |
| Acquisitions (Net) | 0 | 0 | (36.97M) | (33.07M) | 0 |
| Purchases of Investments | 0 | 0 | (127.47M) | (105.29M) | (86.15M) |
| Sales of Investments | 0 | 0 | 118.31M | 98.53M | 81.06M |
| Other Investing Activities | (100M) | (141.66M) | 0 | (26.5M) | (15M) |
| Investing Cash Flow | (100.3M) | (141.83M) | (46.44M) | (67.48M) | (39.65M) |
| Debt Repayment | (500K) | (2M) | (1.25M) | (15M) | (16.25M) |
| Common Stock Issued | 0 | 0 | 0 | 6.5M | 10.21M |
| Common Stock Repurchased | 0 | 0 | (100M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.92M | 8.84M | (3.79M) | (2.5M) | (3M) |
| Financing Cash Flow | 7.42M | 6.84M | (105.55M) | (11M) | (9.05M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.68M | 9.48M | 67.4M | 141.34M | 299.5M |
| Free Cash Flow | 98.26M | 144.29M | 219.08M | 218.67M | 347.89M |
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
Intrinsic Alpha fair value
Locked
Current Price
$33.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.